BRCA1 Monoclonal Antibody (MU), DyLight 650 | Invitrogen MA5-16056 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

BRCA1 Monoclonal Antibody (MU), DyLight 650

catalog :

MA5-16056

quantity :

100 uL

price :

US 474.00

clonality :

monoclonal

host :

mouse

conjugate :

DyLight 650

clone name :

MU

The same clone is also sold as:

OriGene: TA309590
Novus Biologicals: NBP2-80602, NB100-600

reactivity :

human

application :

western blot, immunocytochemistry, flow cytometry

product information

Product Type :

Antibody

Product Name :

BRCA1 Monoclonal Antibody (MU), DyLight 650

Catalog # :

MA5-16056

Quantity :

100 uL

Price :

US 474.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 2-5 ug/mL, Immunocytochemistry: 1:10-1:2,000, Western Blot: 2-4 ug/mL

Species :

Human

Clone :

Isotype :

IgG2b, kappa

Storage :

4 C, store in dark

Description :

BRCA1 (breast and ovarian cancer susceptibility protein 1) is a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor in combination with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as BASC (for BRCA1 associated genome surveillance complex). BRCA1 associates with RNA polymerase II, and through the C terminal domain, also interacts with histone deacetylase complex. The BRCA1 protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in the BRCA1 gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.

Immunogen :

Human BRCA1 (residues 1314-1864).

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 2-5 ug/mL, Immunocytochemistry: 1:10-1:2,000, Western Blot: 2-4 ug/mL

Aliases :

brca 1; Brca1; brca-1; BRCA1, DNA repair associated; BRCA1/BRCA2-containing complex, subunit 1; BRCAI; BRCC1; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein 1; breast cancer 1; breast cancer 1 early onset; breast cancer 1, early onset; breast cancer associated 1; breast cancer type 1 susceptibility protein; Breast cancer type 1 susceptibility protein homolog; BROVCA1; BROVCA12; Delta772-3095; early onset breast cancer 1; Fanconi anemia, complementation group S; FANCS; IRIS; OTTHUMP00000212147; OTTHUMP00000212148; OTTHUMP00000212149; OTTHUMP00000212150; OTTHUMP00000212151; OTTHUMP00000212155; PNCA4; PPP1R53; protein phosphatase 1, regulatory subunit 53; PSCP; RING finger protein 53; RING-type E3 ubiquitin transferase BRCA1; RNF53; truncated BRCA1; truncated breast and ovarian cancer susceptibility protein 1; truncated breast and ovarian cancer sususceptibility protein 1; truncated breast cancer type 1 susceptibility protein